AtaiBeckley Completes Redomiciliation to the United States

Core Viewpoint - AtaiBeckley Inc. has successfully completed its redomiciliation from a Netherlands company to a U.S. entity incorporated in Delaware, aiming to enhance operational efficiency and align with its U.S. shareholder base [1][2][3] Group 1: Redomiciliation Details - The redomiciliation was approved by approximately 99% of votes at the extraordinary general meeting on November 4, 2025 [1] - The exchange of shares was conducted on a one-for-one basis, with former shareholders of Atai Beckley N.V. now holding shares in AtaiBeckley Inc., which continues to trade on NASDAQ under the symbol "ATAI" [2] Group 2: Expected Benefits - The company anticipates that the redomiciliation will lead to cost savings, alignment with its U.S. listing, simplification of corporate structure, and reduced administrative burdens for both the company and its investors [3] Group 3: Company Overview - AtaiBeckley is a clinical-stage biopharmaceutical company focused on developing rapid-acting and convenient mental health treatments, formed through the merger of ATAI Life Sciences N.V. and Beckley Psytech Limited in November 2025 [4] - The company's pipeline includes therapies for treatment-resistant depression and social anxiety disorder, with several candidates currently in Phase 2 clinical development [4]